Brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) are widely used in clinical medicine as diagnostic biomarkers for heart failure (HF) and cardiac dysfunction. In forensic medicine, they can also be used as post-mortem biomarkers to reflect the heart function of the deceased before death. Creative BioMart >Biomarker is capable to provide our customers with superior BNP detection service, various detection methods ensuring high sensitivity for detecting biomarkers in different samples with different concentrations.
Introduction
The natriuretic peptide family mainly includes atrial natriuretic peptide (ANP), which mainly synthesizes and secretes by atrial myocytes, BNP and C-type natriuretic peptide (CNP). BNP is mainly synthesized and secreted by myocytes in the left ventricle (LV) as a response to stretching of myocytes due to pressure overload or ventricular volume expansion. The transcription of BNP mRNA and the synthesis and secretion of BNP proteins occur in an explosive manner, and are quickly released into surrounding tissues after myocardial synthesis. Under pathological conditions, unstable mRNA can quickly synthesize a 134 amino acid BNP precursor (pre-proBNP) and remove the 26-amino acid signal peptide at the N-terminus to form a 108-amino acid BNP (proBNP). The proBNP is split by the proNP convertase, corin or furin, into an inactive 76-amino acid NT-proBNP and an active BNP. BNP and NT-proBNP are detectable in plasma.
Figure 1. brain natriuretic peptide (BNP) structural processing.
NT-proBNP and BNP are considered to be the most valuable and reliable biomarkers for diagnosing HF and cardiac dysfunction. They can also measure the severity of the disease, guide related treatment strategies, and assess the prognosis of heart disease. The 2016 ESC guidelines for diagnosis and treatment of acute and chronic HF, recommend that patients with suspected acute HF should be tested for plasma brain natriuretic peptide levels (BNP and NT-proBNP). BNP levels can help clinicians distinguish the cause of dyspnea is HF or other causes. If BNP< 100 pg/mL, HF is considered unlikely and other causes of dyspnea are sought. If BNP is between 100 and 500 pg/mL, clinical judgment should be used to diagnose HF. If BNP> 500 pg/mL, HF or cardiac dysfunction is considered to be possible, and rapid treatment of HF is recommended.
Application of BNP
Plasma levels of BNP, can be used as a potential biomarker for cardiovascular disease.
Our Advantages
- Accept a wide range of sample types
- Provide multiple detection methods
- Ensure high sensitivity for detecting BNP in different samples
- Ensure high accuracy and repeatable BNP detection
- Ensure a wide kinetic range to detect samples of different concentrations
- Short experimental period
Workflow of BNP Detection at Creative BioMart >Biomarker>
Creative BioMart Biomarker strictly controls each specific experimental step in the BNP detection procedure to ensure high sensitivity, high accuracy and repeatable BNP detection.
Please feel free to contact us if you would like to know more about BNP detection. At Creative BioMart >Biomarker, we not only provide high-quality BNP detection service, but also provide detection services for other biomarkers. Additionally, our experts can also provide and help design the best solution according to your specific requirements.
Reference:
- Cai, Z.; et al. BNP and NT-proBNP as diagnostic biomarkers for cardiac dysfunction in both clinical and forensic medicine. Int J Mol Sci. 2019, 20(8).
